Delivering Discoveries: Moores Cancer Center Annual Impact Report 2024
|
This year’s report highlights Moores’ dedication to cancer prevention, detection, and care through research, advocacy, data, and patient stories. Moores is grateful to its members, faculty, and staff for their continued excellence. View Report>>
|
Butterfly Wings Inspire New Imaging Technique for Cancer Diagnosis
|
Moores Member Jing Yang, PhD collaborated with scientists at UC San Diego Jacobs School of Engineering to create a cost-effective and straightforward method to analyze cancerous tissues by mimicking the nanostructures found on butterfly wings. Learn More>>
|
Moores Cancer Center Kidney Cancer Patient Summit
|
This first-of-its-kind event will take place March 15, 2025 and unite top kidney cancer experts, patients, and caregivers for a day of education, networking, and inspiring stories. Learn More and Register>>
|
Clots and Metastasis in Cancer Patients Start in the Lung
|
Moores Director Diane Simeone, MD took part in a Cornell University-led study that suggests that the lung and thrombosis may play a key role in cancer and metastasis progression. Learn More>>
|
|
|
| Cyclin-dependent kinase 4/6 inhibition as a novel therapy for peritoneal mucinous carcinomatosis with GNAS mutations
|
Journal of Clinical Oncology
|
Jingjing Zou, PhD (Cancer Control), Joel Baumgartner, MD (Solid Tumor Therapeutics [STT]), Rebekah R. White, MD (STT), Gregory P. Botta, MD, PhD (Cancer Biology and Signaling [CBS]), J. Silvio Gutkind, PhD (CBS), Herve Tiriac, PhD (STT), Shumei Kato, MD (Structural and Functional Genomics), and Andrew M. Lowy, MD (STT)
|
|
|
| Mitochondria- and er-associated actin are required for mitochondrial fusion
|
Uri Manor, PhD (Cancer Biology and Signaling)
|
|
|
| The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers
|
Thomas J. Kipps, MD, PhD (Hematologic Malignancies)
|
|
|
CLINICAL TRIALS OFFICE (CTO)
|
D9960C00001: A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)
PI: Benjamin Heyman, MD
NCT: NCT06542250
RMC-LUNG-101: A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
PI: Lyudmila Bazhenova, MD
NCT: NCT06162221
A032102: PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
PI: Rana McKay, MD
NCT: NCT06632977
EAY191-A3: Palbociclib and Binimetinib in RAS-Mutant Cancers: A Combo-MATCH Treatment Trial
PI: Shumei Kato, MD
NCT: NCT05554367
RMC-6236-302: RASolute 302: A Phase III Multicenter, Open-label, Randomized Study of RMC6236 versus Investigators Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
PI: Gregory Botta, MD, PhD
NCT: Not in CTRP
EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2 Gynecologic Cancers and Other Solid Tumors: A Combo-MATCH Treatment Trial
PI: Shumei Kato, MD
NCT: NCT06126276
|
|
|
|
